宣泰医药(688247) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥144,613,579.11, an increase of 40.95% year-over-year, and cumulative revenue for the year-to-date was ¥362,608,213.87, up 69.95% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥38,419,639.84, reflecting an 80.46% increase year-over-year, with a year-to-date net profit of ¥92,572,974.72, up 110.00%[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥36,245,851.54, a 93.81% increase year-over-year, while the year-to-date figure was ¥85,039,247.10, up 130.39%[2]. - Basic earnings per share for Q3 2024 was ¥0.09, an increase of 80.00% year-over-year, with a year-to-date figure of ¥0.21, up 110.00%[3]. - The company reported total operating revenue of CNY 362,608,213.87 for the first nine months of 2024, a significant increase of 69.8% compared to CNY 213,364,344.65 in the same period of 2023[15]. - Total comprehensive income for Q3 2024 was CNY 92,583,577.38, significantly higher than CNY 44,136,578.61 in Q3 2023, marking an increase of 109.1%[18]. - Operating profit for Q3 2024 reached CNY 102,768,011.67, compared to CNY 47,892,033.36 in Q3 2023, reflecting an increase of 114.5%[17]. Research and Development - Total R&D investment for Q3 2024 was ¥22,407,526.38, a 41.76% increase year-over-year, with cumulative R&D investment for the year-to-date at ¥56,471,663.02, up 30.08%[3]. - The proportion of R&D investment to revenue for Q3 2024 was 15.49%, an increase of 0.09 percentage points year-over-year, while the year-to-date ratio was 15.57%, a decrease of 4.77 percentage points[3]. - Research and development expenses for Q3 2024 amounted to CNY 56,471,663.02, up from CNY 43,413,700.00 in Q3 2023, indicating a year-over-year increase of 30.1%[17]. Cash Flow and Assets - The company reported a notable increase in cash flow from operating activities, with a year-to-date net cash flow of ¥87,829,748.53, reflecting a 134.87% increase year-over-year[2]. - The company's cash and cash equivalents decreased to CNY 297,635,969.73 as of September 30, 2024, from CNY 641,783,808.70 at the end of 2023, representing a decline of 53.6%[14]. - The net cash flow from investing activities for the first nine months of 2024 was CNY -377,570,473.13, an improvement compared to CNY -632,217,115.16 in the same period of 2023[21]. - Non-current assets totaled CNY 428,349,025.37 as of September 30, 2024, an increase from CNY 409,611,514.21 at the end of 2023, reflecting a growth of 4.7%[14]. - The total assets of the company reached CNY 1,429,473,540.68, up from CNY 1,361,620,252.55, representing an increase of 5%[14]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,986[8]. - Shanghai Lianhe Investment Co., Ltd. holds 233,000,000 shares, accounting for 51.40% of the total shares[8]. - Finer Pharma Inc. is the second-largest shareholder with 70,437,870 shares, representing 15.54%[9]. - Nanjing Qihe Venture Investment Partnership holds 36,798,000 shares, which is 8.12% of the total[9]. - The company has repurchased 4,336,109 shares, which is 0.96% of the total shares[10]. - The top ten shareholders include various entities, with the largest being state-owned and foreign entities[11]. - The report indicates that there are no significant changes in the shareholding structure compared to the previous period[12]. - The total number of shares held by the top ten unrestricted shareholders is significant, indicating a concentrated ownership structure[11]. Financial Position - Total operating costs for the first nine months of 2024 were CNY 266,457,899.41, up from CNY 174,363,154.22 in the previous year, reflecting a year-over-year increase of 52.8%[15]. - The company's total liabilities amounted to CNY 192,422,177.59, compared to CNY 151,361,317.13 in the previous year, showing an increase of 27.2%[15]. - The company’s retained earnings increased to CNY 282,522,243.15 from CNY 219,593,425.24, reflecting a growth of 28.6% year-over-year[15]. Market Developments - Significant revenue growth was attributed to the successful bidding of ursodeoxycholic acid capsules in the national drug procurement program and the inclusion of posaconazole enteric-coated tablets in the national medical insurance catalog[7]. - The company received formal approval for the Dapagliflozin Metformin Extended-Release Tablets, becoming the first domestic company to obtain approval for this generic drug[13].